Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

The Nasdaq-100 is reconstituted each year in December, timed to coincide with the quadruple witch expiration on the Friday of ...

That’s because the industry veteran will join Alnylam’s board as of Jan. 5. Arbuckle had been executive vice president and ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

Sirnaomics Ltd. ( ($HK:2257) ) has issued an announcement. Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a ...

After a U.S. Court of Appeals Court decision in October that upheld the U.S. Department of Agriculture’s (USDA) ...

PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...

SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the ...

Alnylam Pharmaceuticals is expanding its Norton facility with a $250 million investment to enhance RNAi therapeutic ...

In December 2025, Alnylam Pharmaceuticals announced a US$250 million expansion of its Norton, Massachusetts siRNA manufacturing facility and, together with PeptiDream, achieved a preclinical milestone ...